Clinical Trial

Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

Study acronym: PALLAS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
Trial Details
NCT Number NCT07389980
Lead Sponsor Yeungnam University College of Medicine
Collaborators: Bayer
Conditions Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Enrollment 50 participants
Start Date 2026-12-24
Primary Completion 2028-11 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-05